JPMorgan adds this 'unloved' value stock to its favorite buys list

JPMorgan added Celanese to its focus list, reiterating an overweight rating and raising its price target to $76 from $68, implying ~76% upside from Wednesday’s close. The note cites likely upside to 2026 earnings from Acetyl Chain margin lift driven by price inflation in acetic acid derivatives (e.g., VAM/VAE) and improved Engineered Materials volumes supported by medical and electronics demand. Despite better-than-expected Q2 results, investors remain concerned about leverage, with shares down ~10% in 2026 year-to-date.

Analysis

The market is likely treating CE like a balance-sheet story when it is increasingly an earnings-recapture story. In the next 1-2 quarters, the stock can stay rangebound because leverage suppresses multiple expansion, but the operating setup is asymmetric: a modest improvement in acetyl pricing plus mix shift toward higher-value medical/electronics can lever free cash flow faster than headline revenue suggests. That makes CE a candidate for sharp rerating on any evidence that 2026 margins are inflecting before debt metrics fully normalize.

The more interesting second-order effect is competitive: if CE’s acetyl chain tightens into 2026, downstream buyers may delay purchases or source substitution from imports, which can cap pricing durability for a few quarters. On the engineered materials side, growth in medical and electronics should be read as a quality-of-demand signal for specialty polymers broadly; it is supportive for peers with similar exposure, but CE’s leverage means it will outperform only if the market believes the improvement is self-funded rather than cycle-dependent. Eastman-style peers with cleaner balance sheets could look relatively safer, but CE has more torque if the thesis works.

Contrarian risk: consensus may be underestimating how much working capital and interest expense can dilute the benefit of better prices. If acetic acid inflation is driven by supply rather than end-demand, the cash conversion may disappoint even as gross profit improves. The thesis is falsified if 1) acetyl pricing rolls over by mid-2026, 2) medical/electronics growth decelerates for two consecutive quarters, or 3) net debt/EBITDA fails to trend meaningfully lower by the next refinancing window.

Key Decisions for Investors

• Initiate a tactical long CE on any post-rally pullback, targeting a 3-6 month window; use the stock as a levered call on 2026 margin re-rate, but keep size modest because leverage can cap the multiple.
• Prefer a CE Jan-2027 call spread over outright equity if you want convexity to the 2026 earnings inflection; risk/reward is better if the market continues to underwrite only the leverage overhang.
• Watch-list, not trade: if CE reports two straight quarters of improving medical/electronics mix and lower net debt/EBITDA, add on confirmation; if not, the bull case is probably just a valuation trap.
• For a relative-value expression, consider long CE vs. a cleaner but less torqued specialty-chemicals basket/ETF proxy such as XLB; CE should outperform if acetyl pricing and specialty mix inflect, underperform if the market stays credit-focused.